People

Tom Hughes jumps ship at Zafgen and gets back to the helm of a noteworthy biotech

The battle-tested biotech exec Tom Hughes is headed back to a CEO post.

After leading Zafgen through an IPO, a savage safety crisis and a complete revamp, Hughes stepped down from the CEO role at Zafgen several months ago to take the chief scientific officer’s job as Jeffrey Hatfield was named CEO. Now he’s relocating to another Cambridge/Boston biotech outfit called Navitor, which has just launched its first early-stage clinical study to test the anti-aging theories it’s been working on for the past 4 years.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 33,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Clinical Scientist
Molecular Templates Jersey City, NJ
Manufacturing Associate - GMP Upstream
Molecular Templates Austin, TX
Director, Regulatory Affairs
Molecular Templates Jersey City, NJ
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Manufacturing Associate - GMP Downstream
Molecular Templates Austin, TX

Visit Endpoints Careers ->